SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:0270 4137 OR L773:1097 0045
 

Sökning: L773:0270 4137 OR L773:1097 0045 > (2010-2014) > Inhibition of metas...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004929naa a2200505 4500
001oai:lup.lub.lu.se:07523bdc-04c7-4a22-9cdf-92fba9c97710
003SwePub
008160401s2012 | |||||||||||000 ||eng|
009oai:gup.ub.gu.se/156536
0247 a https://lup.lub.lu.se/record/25629652 URI
0247 a https://doi.org/10.1002/pros.214952 DOI
0247 a https://gup.ub.gu.se/publication/1565362 URI
040 a (SwePub)lud (SwePub)gu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Jennbacken, Karin,d 1978u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institute of Clinical Sciences, Department of Urology4 aut0 (Swepub:gu)xjenka
2451 0a Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050)
264 c 2011-10-05
264 1b Wiley,c 2012
520 a BACKGROUND Tasquinimod (ABR-215050) is an orally active quinoline-3-carboxamide analog that has completed phase II clinical trial in patients with castration resistant prostate cancer, showing promising inhibiting effects on the occurrence of metastasis and delayed disease progression. Its mechanism of action is not fully elucidated, but previous studies show anti-angiogenic effects and strong interaction with the S100A9 protein. METHODS This study was performed to evaluate if tasquinimod inhibits prostate cancer metastasis, by using both orthotopic and intratibial xenograft models. Animals were treated with tasquinimod, and tumor growth characteristics as well as molecular markers for metastasis and angiogenesis were analyzed. RESULTS The results show that formation of lung and lymph node metastases from orthotopic castration resistant prostate tumors was inhibited by tasquinimod treatment. Importantly, establishment of tumors in the bone after intratibial implantation was suppressed by tasquinimod. In addition, establishment and growth of subcutaneous tumors were affected. Both in primary tumors and serum from treated mice an upregulation of thrombospondin 1 was observed. Further, downregulation of the hypoxia driven genes VEGF, CXCR4, and LOX was detected in the primary tasquinimod-treated tumors and decreased expression of chemotactic ligand SDF-1 was demonstrated in the lungs. Thus, these molecular changes could contribute to the anti-angiogenic and anti-metastatic effects of tasquinimod. CONCLUSIONS In conclusion, this study and clinical data show that tasquinimod interferes with the metastatic process, presumably by inhibition of tumor establishment. Therefore, tasquinimod is an interesting treatment option for patients with prostate cancer prone to metastasis. Prostate 72:913924, 2012. (C) 2011 Wiley Periodicals, Inc.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reproduktionsmedicin och gynekologi0 (SwePub)302202 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Obstetrics, Gynaecology and Reproductive Medicine0 (SwePub)302202 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Urologi och njurmedicin0 (SwePub)302142 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Urology and Nephrology0 (SwePub)302142 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a angiogenesis
653 a thrombospondin
653 a CXCR4
653 a bone metastasis
653 a angiogenesis; thrombospondin; CXCR4; bone metastasis
7001 a Welén, Karin,d 1970u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institute of Clinical Sciences, Department of Urology4 aut0 (Swepub:gu)xwelka
7001 a Olsson, Anders4 aut
7001 a Axelsson, Bengt4 aut
7001 a Torngren, Marie4 aut
7001 a Damber, Jan-Erik,d 1949u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institute of Clinical Sciences, Department of Urology4 aut0 (Swepub:gu)xdamja
7001 a Leanderson, Tomasu Lund University,Lunds universitet,Immunologi,Forskargrupper vid Lunds universitet,Immunology,Lund University Research Groups4 aut0 (Swepub:lu)immu-tle
7102 a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för urologi4 org
7730 t The Prostated : Wileyg 72:8, s. 913-924q 72:8<913-924x 0270-4137x 1097-0045
8564 u http://dx.doi.org/10.1002/pros.21495y FULLTEXT
8564 8u https://lup.lub.lu.se/record/2562965
8564 8u https://doi.org/10.1002/pros.21495
8564 8u https://gup.ub.gu.se/publication/156536

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy